Phosphodiesterase Type 5 Inhibitors for the Treatment of Male Lower Urinary Tract Symptoms

Documenti analoghi

• Update on Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia
  di: Elterman, Dean S, et al.
  Pubblicazione: (2012)
• Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia, Erectile Dysfunction, and Phosphodiesterase-5 Inhibitors
  di: Roehrborn, Claus G
  Pubblicazione: (2004)
• The role of phosphodiesterase type-5 inhibitors in treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia
  di: Umul, Mehmet, et al.
  Pubblicazione: (2013)
• The use of antimuscarinics, phosphodiesterase type V inhibitors and phytotherapy for lower urinary tract symptoms in men
  di: Ng, Kok Kit, et al.
  Pubblicazione: (2017)
• Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia
  di: Pattanaik, Smita, et al.
  Pubblicazione: (2018)